apatinib: Clinical Trials

63 trials of apatinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

28 unknown, 13 recruiting, 8 active not recruiting, 8 completed. 63 Phase 3, 19 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 363Unknown 28, Recruiting 13, Active not recruiting 8, Completed 8, Not yet recruiting 4, Terminated 2
Phase 219Unknown 8, Recruiting 5, Active not recruiting 2, Completed 2, Not yet recruiting 2

Follow apatinib: new trials by email Literature Review of apatinib trials Research Report on apatinib

Trials (filtered) newest first · largest first

All 63 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Apatinib Mesylate Tablets - Gastric Cancer, Surgery
Phase 3Not yet recruitingFujian Medical University1182026-12-252026-01-02
Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer
Afatinib + Toripalimab, Dalpiciclib + Pyrotinib, Camrelizumab + Apatinib - Esophageal Squamous Cell Carcinoma
Phase 2 / Phase 3Not yet recruitingPeking University Cancer Hospital & Institute902026-07-012026-06-17
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
VRT106, VRT106 in combination with camrelizumab and apatinib, Investigator's Choice of Standard of Care - HCC
Phase 2 / Phase 3RecruitingGuangzhou Virotech Pharmaceutical Co., Ltd.662026-05-132026-10-30
A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
Apatinib, Camrelizumab, TACE - Hepatocellular Carcinoma
Phase 2 / Phase 3Not yet recruitingShanghai Zhongshan Hospital2222025-12-222025-12-30
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
Infusional mFOLFOX7 plus Camrelizumab and apatinib, Camrelizumab and apatinib - Hepato Cellular Carcinoma (HCC), Chemotherapy Effect
Phase 3RecruitingLinhui Peng3262025-10-312025-12-16
Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
camrelizumab combined with rivoceranib and HAIC, camerlizumab + rivoceranib - Potentially Resectable Hepatocellular Carcinoma
Phase 2 / Phase 3RecruitingShanghai Zhongshan Hospital3982025-02-202026-07-17
Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
Fluzoparib Capsules, Apatinib Mesylate Tablets - Ovarian Cancer
Phase 3Not yet recruitingThe First Affiliated Hospital of Xiamen University372024-12-012024-01-03
Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer
Fluzoparib, Apatinib Mesylate - Epithelial Ovarian Cancer, Efficacy
Phase 3UnknownAnhui Provincial Hospital512024-10-012024-08-06
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
TACE plus camrelizumab and apatinib, Camrelizumab and apatinib - Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization
Phase 3RecruitingGuohui Xu1012024-08-102026-04-14
LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.
LM-302, Apatinib, Irinotecan - Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
Phase 3Active not recruitingLaNova Medicines Zhejiang Co., Ltd.3872024-06-242026-02-06
Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer
Chemotherapy/ADC Regimen, Fluorizoparib, Apatinib - Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer
Phase 3Active not recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2002024-06-122026-01-28
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Fluzoparib, Apatinib Mesylate, Capecitabine tablets - Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer
Phase 3RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2002024-06-122025-08-15
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Apatinib, CDK4/6 Inhibitor, Aromatase inhibitor and Fulvestrant - Advanced Breast Cancer, HR+/HER2- Breast Cancer
Phase 3Active not recruitingFudan University1842024-06-112026-09-25
Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
TPC combined with Apatinib and Camrelizumab, GP Combined With Camrelizumab - Nasopharyngeal Carcinoma
Phase 3RecruitingXIANG YANQUN1642024-05-302024-07-16
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AZD0901, Ramucirumab+ paclitaxel, Paclitaxel - Gastric Cancer, Gastroesophageal Junction Cancer
Phase 3Active not recruitingAstraZeneca5942024-03-042026-10-15
Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
intravenous FOLFOX7 plus Camrelizumab and apatinib, HAIC-FOLFOX plus Camrelizumab and apatinib - BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect
Phase 3RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2622023-07-012025-12-03
A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer
Standard endocrine therapy plus Apatinib - HR+/HER2-breast Cancer
Phase 3UnknownFudan University9162023-06-012023-06-05
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Tislelizumab, apatinib, oxaliplatin - Immunotherapy Gastrict Cancer
Phase 2 / Phase 3RecruitingFujian Cancer Hospital1302023-05-102024-05-01
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
Camrelizumab, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma
Phase 3RecruitingSun Yat-sen University2442023-05-012023-05-11
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Camrelizumab, Apatinib Mesylate, Radical surgery - Hepatocellular Carcinoma, Immunotherapy
Phase 3RecruitingThe First Affiliated Hospital with Nanjing Medical University1302023-01-312024-12-31

Showing 20 of 63. Sign in to see all of them.

Conditions studied

Stomach Neoplasms (15)  ·  Carcinoma, Hepatocellular (9)  ·  Breast Neoplasms (4)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Neoplasm Metastasis (4)  ·  Ovarian Neoplasms (3)  ·  Esophageal Neoplasms (2)  ·  Nasopharyngeal Carcinoma (2)  ·  Neoplasms (2)  ·  Small Cell Lung Carcinoma (2)  ·  Adenocarcinoma (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Digestive System Neoplasms (1)  ·  Esophageal Squamous Cell Carcinoma (1)  ·  Fallopian Tube Neoplasms (1)

Sponsors

Jiangsu HengRui Medicine Co., Ltd. (13)  ·  Sun Yat-sen University (5)  ·  Fudan University (4)  ·  Shanghai Zhongshan Hospital (4)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (4)  ·  Tianjin Medical University Cancer Institute and Hospital (3)  ·  Hebei Medical University (2)  ·  Anhui Provincial Hospital (1)  ·  AstraZeneca (1)  ·  Beijing Chest Hospital (1)  ·  Elevar Therapeutics (1)  ·  Feng Wang (1)  ·  Fujian Cancer Hospital (1)  ·  Fujian Medical University (1)  ·  Fuzhou General Hospital (1)

Countries

China (51)  ·  Germany (3)  ·  Italy (3)  ·  Poland (3)  ·  South Korea (3)  ·  Taiwan (3)  ·  United States (3)  ·  France (2)  ·  Hong Kong (2)  ·  Japan (2)  ·  Russia (2)  ·  Spain (2)  ·  Turkey (Türkiye) (2)  ·  Ukraine (2)  ·  United Kingdom (2)

Top investigators

Jin Li, MD, PHD (2)  ·  Shukui Qin, MD (2)  ·  Bang-De Xiang, Ph.D (1)  ·  Chunmei Bai (1)  ·  Feng Wang (1)  ·  Guohui Xu (1)  ·  Han Liang, Master (1)  ·  Hongyun Zhao (1)  ·  Jian Zhou, Doctor (1)  ·  Jianli Zhao (1)  ·  Jianming Xu, Ph.D (1)  ·  Jin Li (1)  ·  Li Zhang, MD (1)  ·  Liang Peng (1)  ·  Liu Tianshu, doctor (1)

Results publications

PMID 14745444, PMID 20876799, PMID 21443688, PMID 22212563, PMID 23918952, PMID 26020064, PMID 31699150, PMID 32171104, PMID 32508029, PMID 33067126, PMID 33323401, PMID 33490196, PMID 33971141, PMID 34033974, PMID 34913959, PMID 35909569, PMID 37499670, PMID 39232496, PMID 39383487, PMID 39924483, PMID 39961962, PMID 40341124, PMID 41125112, PMID 41308673, PMID 41308676, PMID 41819560

NIH funding

2023 (1)